The victim list, which was posted to Clop’s dark web leak site, includes U.S.-based financial services organizations 1st Source and First National Bankers Bank Boston-based investment management firm Putnam Investments the Netherlands-based Landal Greenparks and the U.K.-based energy giant Shell. While the exact number of victims remains unknown, Clop on Wednesday listed the first batch of organizations it says it hacked by exploiting the MOVEit flaw. Progress Software, which develops the MOVEit software, patched the vulnerability - but not before hackers compromised a number of its customers. The Russia-linked ransomware gang has been exploiting the security flaw in MOVEit Transfer, a tool used by corporations and enterprises to share large files over the internet, since late May. But Elevidys will become the second most expensive drug in the world, after the $3.5 million hemophilia treatment Hemgenix.Clop, the ransomware gang responsible for exploiting a critical security vulnerability in a popular corporate file transfer tool, has begun listing victims of the mass-hacks, including a number of U.S. While eye-popping, such a pricetag isn’t out of step with other one-time gene therapies, which have topped $3 million per patient in recent years. He had estimated that Sarepta would price the drug at $2.8 million per patient, which could bring in $2.1 billion in revenue from the initial group eligible for the drug. The group for whom the drug was approved, children ages 4 and 5, is about 6% of the population of people with Duchenne muscular dystrophy, according to Brian Abrahams, an analyst with Wall Street firm RBC Capital Markets. Sarepta said the therapy, called Elevidys, will cost $3.2 million per patient. It affects an estimated one in 3,300 boys. It was the first time a therapy of this nature – a one-time treatment that delivers a working copy of a gene to make up for one that leads to disease – has been cleared under the accelerated approval framework, and the move came after emotional testimonials from families at an FDA advisory committee meeting last month.ĭuchenne muscular dystrophy causes progressive muscle weakness that can rob kids of their ability to walk by the time they’re teenagers, and many don’t live well into their 30s. The therapy was approved under the accelerated approval pathway, which clears medicines for diseases where they’re urgently needed based on data suggesting they’re likely to confer clinical benefits.
Nova health ltd trial#
The drug, from biotech company Sarepta Therapeutics, will need to prove in an ongoing clinical trial that it improves physical function and mobility in patients with Duchenne muscular dystrophy in order to stay on the market, the FDA said Thursday. FDA advisers narrowly vote in favor of experimental gene therapy for rare muscle disease
0 kommentar(er)
